Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Verona Pharma PLC ADR

Healthcare US VRNA

NoneUSD
0.00(0%)

Last update at 2025-11-06T20:10:52.435910Z

Day Range

--
LowHigh

52 Week Range

11.8323.07
LowHigh

Fundamentals

  • Previous Close 86.00
  • Market Cap1013.12M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-72.50275M
  • Revenue TTM0.46M
  • Revenue Per Share TTM0.006
  • Gross Profit TTM 0.11M
  • Diluted EPS TTM-0.8

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -68.44800M -55.58700M -65.00000M -51.40557M -30.62253M
Minority interest - - - 0.00000M 0.00000M
Net income -68.70100M -55.56900M -65.14600M -41.87995M -25.25251M
Selling general administrative 26.58M 33.91M 29.77M 8.99M 7.99M
Selling and marketing expenses - - - - -
Gross profit 0.11M 40.00M 0.00235M 0.00235M 0.00278M
Reconciled depreciation 0.64M 0.63M 0.62M 0.66M 0.12M
Ebit -66.11600M -73.31300M -74.27700M -53.86663M -31.39148M
Ebitda -62.65900M -57.04000M -65.26600M -51.76483M -31.26713M
Depreciation and amortization 3.46M 16.27M 9.01M 2.10M 0.12M
Non operating income net other - - - 0.00000M 0.00000M
Operating income -66.11600M -73.31300M -74.27700M -53.86663M -32.47259M
Other operating expenses 66.57M 97.68M 66.01M 53.41M 32.48M
Interest expense 0.52M 0.34M 0.04M 0.22M 0.13M
Tax provision 0.25M -0.01800M 0.15M -7.26500M -4.23200M
Interest income 2.82M 0.01M 0.12M 0.75M 0.86M
Net interest income 2.30M -0.32600M 0.09M 0.58M 0.76M
Extraordinary items - - - 0.00000M 0.00000M
Non recurring - - - 0.00000M 0.00000M
Other items - - - 0.00000M 0.00000M
Income tax expense 0.25M -0.01800M 0.15M -9.52562M -5.37001M
Total revenue 0.46M 40.00M 0.00235M 0.00235M 0.00278M
Total operating expenses 66.23M 97.68M 66.01M 53.41M 32.48M
Cost of revenue 0.35M - - 0.00000M 0.00000M
Total other income expense net -2.33200M 17.73M 9.28M 2.46M 1.85M
Discontinued operations - - - 0.00000M 0.00000M
Net income from continuing ops -68.70100M -55.56900M -65.14600M -31.94100M -19.90100M
Net income applicable to common shares -68.70100M -55.56900M -65.14600M -40.56100M -19.90100M
Preferred stock and other adjustments - - - 0.00000M 0.00000M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 308.12M 259.47M 186.59M 204.21M 59.18M
Intangible assets - - - 3.61M 3.61M
Earning assets - - - - -
Other current assets 6.98M 3.39M 2.06M 1.72M 0.01M
Total liab 58.84M 29.00M 38.58M 19.35M 14.78M
Total stockholder equity 249.28M 230.47M 148.00M 184.85M 44.40M
Deferred long term liab - - - - 0.00000M
Other current liab 4.02M 15.44M 0.33M 2.36M 10.10M
Common stock 42.77M 40.53M 31.86M 31.79M 6.90M
Capital stock 42.77M 40.53M 31.86M 31.79M 6.90M
Retained earnings -388.43300M -333.09700M -263.71600M -207.05000M -131.93869M
Other liab - - - - 1.16M
Good will 0.55M 0.55M 0.55M 0.55M 0.58M
Other assets 0.00000M - - 1.16M 0.00000M
Cash 271.77M 227.83M 148.38M 187.99M 30.07M
Cash and equivalents - - - - -
Total current liabilities 8.69M 19.03M 33.42M 14.20M 12.61M
Current deferred revenue 0.00000M - 22.40M 10.86M 0.00000M
Net debt -220.44300M -217.17900M -142.57200M -182.03900M -28.82336M
Short term debt 1.18M 0.68M 0.65M 0.80M 0.60M
Short long term debt - - - - 0.00000M
Short long term debt total 51.33M 10.65M 5.81M 5.95M 1.25M
Other stockholder equity 599.55M 527.64M 384.47M 364.71M 169.44M
Property plant equipment - 0.93M 0.98M 1.16M 1.35M
Total current assets 289.71M 243.00M 170.06M 202.50M 53.66M
Long term investments 15.00M 15.00M 15.00M - 0.00000M
Net tangible assets - 229.92M 167.66M 184.31M 42.16M
Short term investments - - - 10.26M 10.26M
Net receivables 10.95M 9.28M 15.58M 8.26M 9.81M
Long term debt 48.37M 9.77M 4.87M 4.63M 0.00000M
Inventory 0.00000M 2.50M 4.04M 4.54M 0.00000M
Accounts payable 3.49M 2.91M 10.04M 0.18M 1.91M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income -4.60100M -4.60100M -4.60100M -4.60100M 0.00000M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - - - 0.00000M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - - - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other 15.02M 15.07M 15.08M - 0.97M
Deferred long term asset charges - - - - 0.00000M
Non current assets total 18.42M 16.47M 16.52M 1.70M 5.52M
Capital lease obligations 2.96M 0.88M 0.93M 1.31M 0.95M
Long term debt total - - - - 0.49M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.02900M -0.01200M 9.71M 37.80M 5.28M
Change to liabilities -7.14600M 9.87M -1.39800M -1.73400M 0.53M
Total cashflows from investing activities -0.02900M -0.01200M 9.71M 47.31M 5.28M
Net borrowings 4.15M 4.15M 5.00M 5.00M 5.00M
Total cash from financing activities 140.82M -6.11700M 192.34M -0.55856M -3.81559M
Change to operating activities -7.69200M 10.36M -1.48300M 1.39M -0.64000M
Net income -68.70100M -55.56900M -65.14600M -51.40557M -30.62253M
Change in cash 79.45M -39.60600M 157.56M 4.13M -14.79418M
Begin period cash flow 148.38M 187.99M 30.43M 25.94M 39.90M
End period cash flow 227.83M 148.38M 187.99M 30.07M 25.10M
Total cash from operating activities -59.86200M -33.25400M -45.07600M -44.34363M -22.98117M
Issuance of capital stock 149.80M 0.73M 200.16M 0.00000M 0.00000M
Depreciation 0.64M 0.63M 0.62M 0.66M 0.12M
Other cashflows from investing activities - - - 0.89M 0.88M
Dividends paid - - - 0.00000M 0.00000M
Change to inventory - - - 0.00000M 0.00000M
Change to account receivables - - 0.00000M -0.48400M -0.64000M
Sale purchase of stock - - - 0.00000M 0.00000M
Other cashflows from financing activities -3.97900M -6.85000M -7.81300M -0.55813M 6.70M
Change to netincome 18.86M 8.13M 21.55M 1.45M 1.80M
Capital expenditures 0.03M 0.01M 0.08M 0.37M 0.34M
Change receivables - - - 0.00000M 0.00000M
Cash flows other operating - - - 0.00000M 0.00000M
Exchange rate changes - - - 0.00000M 0.00000M
Cash and cash equivalents changes - - - 0.00000M 0.00000M
Change in working capital -10.73800M 13.44M -2.11300M -0.04589M -0.13831M
Stock based compensation 14.12M 25.43M 22.18M 3.20M 3.68M
Other non cash items 4.82M 0.24M 0.02M -2.46106M -1.85007M
Free cash flow -59.89100M -33.26600M -45.15800M -44.71338M -23.32124M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
VRNA
Verona Pharma PLC ADR		 - -% - - - 3098.64 5.17 2531.50 -20.8755
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

Verona Pharma PLC ADR

3 More London Riverside, London, United Kingdom, SE1 2RE

Key Executives

Name Title Year Born
Dr. David S. Zaccardelli Pres, CEO & Exec. Director 1965
Mr. Mark W. Hahn Chief Financial Officer 1963
Dr. Kathleen A. Rickard Chief Medical Officer 1958
Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA Gen. Counsel 1967
Ms. Victoria Stewart Director of Communications NA
Mr. Matthew Casbon VP of Sales, Marketing & Training NA
Ms. Ostra Jewell Sr. VP of HR NA
Dr. Peter Spargo Sr. VP of Chemistry Manufacturing & Controls 1962
Dr. Tara Rheault M.P.H., Ph.D. Sr. VP of R&D 1977
Ms. Nina Church Exec. Director of Global Clinical Devel. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.